Nearly a year ago today I attended a conference on biotechnology in Sydney. I noticed how many of the people who worked in the industry, or were closely following developments as an investor in the sector, had become much less optimistic than in the year before.

The story I wrote following the conference opened with the sentence: “Biotechnology stocks are the pariah in today’s financial industry”. I explained it was my view that at a time when China had awoken and India would soon follow there was little or no room left in the world of finance for what I described as “Big Dreams with no revenues, and even less money”.

Little did I know how right I was at the time, I came to realise this week. First there was the announcement by Standard and Poor’s regarding the latest changes to the major stock indices in Australia. I have seen nobody else picking it up yet, but with the removal of Novogen (NRT) from the S&P/ASX200 index also disappears the last biotech stock from Australia’s leading share index.

There's more to Crikey than you think.

Get more and save 50%.

Subscribe now

I checked today, and the S&P/ASX300 index still has a handful biotechs including Biota (BTA), Cellestis (CST), Metabolic Pharmaceuticals (MBP) and Pharmaxis (PXS), but that’s about it from now on.

The news about a biotech-less S&P/ASX200 had hardly sunk in or an email entered my inbox announcing the silent death of the weekly Biotech Buzz, one of the most highly appreciated email newsletters on the industry.

I spoke to the author, Southern Cross Equities analyst Stuart Roberts, on Monday. He explained the decision with a healthy dose of humour: “the sector can continue languishing without me”. Stuart says he received about 120 emails following the announcement that he had quit spending his time on researching biotechnology hopefuls.

Anyone interested in a fundamental investment opinion on the likes of Progen (PGL) or Peptech (PTD) will now have to turn to Taylor Collison or ABN Amro Morgans, or some part-time efforts at Intersuisse and Shaw Stockbroking.

As far as my knowledge goes, that’s all that’s left now, apart from magazine Bioshares, which enjoys a respectable reputation in both the biotech and financial sector. A few weeks ago Bioshares zoomed in on the fact that, regardless of all the previous paragraphs, the global biotech industry had been caught by a wave of merger and acquisitions as well. The magazine commented all targets were revenue generating, even profitable businesses “that have arguably been trading at significant discounts to their inherent value”.

Bioshares believes two local companies stand out as potential takeover targets: Optiscan Imaging (OIL) and Clinical Cell Culture (CCE). ABN Amro Morgans analysts Scott Power and Tanya Solomon responded with saying they would add SDI Ltd (SDI) to make it a threesome.

Bioshares noted that Acrux (ACR), Cytopia (CYT), Alchemia (ACL) and Avexa (AVX) might also appear on the radars of “aggressive international buyers”. In other words, it’s all not just about Coles (CML), Colorado (CDO) or S8 (SEL) – or Rinker (RIN) or Repco (RCL) or Terramin (TZN) or Jubilee Mines (JBM) – but just as much about those that have landed, as I wrote a year ago, “in the darkest corner of the stockmarket”.

Whatever happens to the local biotech industry, from now on it will have to do so without the contagious enthusiasm of Stuart Roberts, who has moved on to become a healthcare analyst.

There's more to Crikey than you think.

It’s more than a newsletter. It’s where readers expect more – fearless journalism from a truly independent perspective. We don’t pander to anyone’s party biases. We question everything, explore the uncomfortable and dig deeper.

And now you get more from your membership than ever before.

Peter Fray
Peter Fray
Editor-in-chief of Crikey
Get more and save 50%